The effect of β3-AR Trp64Arg on rosiglitazone response in T2DM patients

Aim: To explore the impact of β3-adrenergic receptor (ADRB3) genetic variation on therapeutic efficacy of rosiglitazone in Chinese T2DM patients. Methods: The genotypes of ADRB3 Trp64Arg in 255 T2DM patients and 148 healthy volunteers were determined by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Samples were randomly selected for direct DNA sequencing to identify the results of PCR-RFLP assay. 34 T2DM patients administrated orally 4 mg rosiglitazone daily for 12 consecutive weeks. The concentrations of fasting plasma glucose, postprandial plasma glucose, glycated hemoglobin, fasting serum insulin, postprandial serum insulin and so on in all T2DM subjects were determined before and after rosiglitazone treatment for 12 consecutive weeks. Results: There were no significant differences in the distributive frequency of the ADRB3 Trp64Arg polymorphisms between T2DM patients and controls. Our results showed that ADRB3 Trp64Arg had bigger attenuated serum triglyceride (P < 0.05) and smaller attenuated low-density lipoprotein-cholesterol (P < 0.01) as well as smaller enhanced adiponectin (P < 0.05) compared with ADRB3 Trp64Atrp. Conclusion: ADRB3 Trp64Arg genetic polymorphism are associated with therapeutic efficacy of multiple-dose rosiglitazone in Chinese T2DM patients.

Duke Scholars

Author Huihua Li Pathology